THE INFLUENCE OF THE LENGTH OF METHADONE MAINTENANCE TREATMENT ON QUALITY OF LIFE OF OPIOID ADDICTS
Abstract
Abstract
Background: Given the chronic and relapsing nature of addiction diseases and the various life domains they affect, the interest for quality of life research in the field of drug abuse has grown rapidly.
Aim: Evaluation and comparison of quality of life in opioid addicts who are on methadone maintenance therapy for no longer than 2 years, from 2 to 5 years, or more than 5 years.
Methods: A cross sectional study was conducted in May 2013. Data were obtained by anonymous survey of 78 patients who were involved in methadone maintenance treatment. Patients were divided into three groups (n = 26) depending on the length of treatment. Quality of life of the patients was assessed by WHOQOL-BREF (World Health Organization Quality of Life) questionnaire.
Results: Patients who are treated with methadone for 2 years or less, reported higher scores in almost all aspects of quality of life. Higher scores in the physical, social and environment domains were recorded in patients who are treated from 2 to 5 years than the patients who are treated for more than 5 years. However, these differences were not statistically significant. The most common side effects during therapy were constipation (32.1%), sweating (32.1%) and difficulty falling asleep and maintaining sleep (30.8%).
Conclusion: Patients showed no statistically significant difference of quality of life in relation to the length of methadone maintenance treatment.References
Padaiga Ž, Subata E, Vanagas G. Outpatient methadone maintenance treatment program - quality of life and health of opioid-dependent persons in Lithuania. Medicina (Kaunas) 2007; 43(3): 235-41.
Brown R. Heroin dependence. Wisconsin Medical Jour-nal 2004; 103(4): 20-6.
van den Brink W, Goppel M, van Ree JM. Management of opioid dependence. Curr Opin Psychiatry 2003; 16(3) Preuzeto sa: http://www.medscape.com/viewarticle/452723
Ward J, Hall W, Mattick RP. Role of maintenance treat-ment in opioid dependence. Lancet 1999; 353: 221-6.
de Maeyer J, Vanderplasschen W, Lammertyn J, van Nieuwenhuizen C, Sabbe C, Broekaert E. Current quality of life and its determinants among opiate-de-pendent individuals five years after starting methadone treatment. Qual Life Res 2011; 20: 139-50.
Stojiljković MP, Lončar-Stojiljković D, Đukić-Dejano-vić SM. Medikamentozna terapija bolesti zavisnosti. U: Đukić-Dejanović SM, Janković SM, urednici. Medikamentozna terapija u psihijatriji. Drugo izdanje. Kragujevac. 2005. str. 302-22.
The WHOQOL Group. Development of the World Health Organization WHOQOL-BREF quality of life assessment. Psychol Med 1998; 28: 551-8.
Luty J, Arokiadass SMR. Satisfaction with life and opioid dependence. Subst Abuse Treat Prev and Policy 2008; 3: 2.
Fassino S, Abbate DG, Delsedime N, Rogna L, Boggio S. Quality of life and personality disorders in heroin abusers. Drug Alcohol Depend 2004; 76(1): 73-80.
Yen C, Wang CS, Wang T, Chen H, Chang H. Quality of life and its correlates among heroin users in Taiwan. Kaohsiung Journal of Medical Sciences 2011; 27: 177-83.
Xiao L, Wu Z, Luo W, Wei X. Quality of life of outpa-tients in methadone maintenance treatment clinics. J Acquir Immune Defic Syndr 2010; 53 Suppl 1: S116-20.
Maremmani I, Pani PP, Pacini M, Perugi G. Substance use and quality of life over 12 months among bupre-norphine maintenance-treated and methadone mainte-nance-treated heroin-addicted patients. J Subst Abuse Treat 2007; 33: 91-8.
Baharom N, Hassan MR, Ali N, Shah SA. Improve-ment of quality of life following 6 months of methadone maintenance therapy in Malaysia. Subst Abuse Treat Prev and Policy 2012; 7: 32.
Ponizovsky AM, Grinshpoon A. Quality of life among heroin users on buprenorphine versus methadone maintenance. Am J Drug Alcohol Abuse 2007; 33: 631-42.
Habrat B, Chmielewska K, Baran-Furga H, Keszycka B, Taracha E. Subjective quality of life in opiate-dependent patients before admission after six months and one-year participation in methadone program. Przegl Lek 2002; 59: 351-4.
Giacomuzzi SM, Ertl M, Kemmler G, Riemer Y, Vigl A. Sublingual buprenorphine and methadone mainte-nance treatment: A three-year follow-up of quality of life assessment. Scientific World Journal 2005; 5: 452-68.
Faul F, Erdfelder E, Lang A, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007; 39(2): 175-91.
Acton C, Miller R. SPSS for social scientists, 2nd ed. Basingstoke: Palgrave Macmillan. 2009.
Schroeder JR, Schmittner JP, Epstein DH, Preston KL. Adverse events among patients in a behavioral treatment trial for heroin and cocaine dependence: effects of age, race, and gender. Drug Alcohol Depend 2005; 80(1): 45-51.
Brown R, Balousek S, Mundt M, Fleming M. Metha-done maintenance and male sexual dysfunction. J Addict Dis 2005; 24(2): 91-106.